ParkinsonFranceV1, PascalFrancis, Checkpoint, bibRecord, 001742

Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice

Identifieur interne : 001742 ( PascalFrancis/Checkpoint ); précédent : 001741; suivant : 001743

Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice

Auteurs : B. Naudin [France] ; J.-J. Bonnet ; J. Costentin

Source :

Brain research [ 0006-8993 ] ; 1995.

RBID : Pascal:96-0044785

Descripteurs français

Pascal (Inist)
- Neurone dopaminergique, Voie nigrostriatale, Dopa, Traitement, Chimiothérapie, Dopamine, Antiparkinsonien, Potentialisation, Parkinson maladie, Oxidopamine, Toxicité, Animal, Souris.

English descriptors

KwdEn :
- Animal, Antiparkinson agent, Chemotherapy, Dopa, Dopamine, Dopaminergic neuron, Mouse, Nigrostriatal pathway, Oxidopamine, Parkinson disease, Potentiation, Toxicity, Treatment.

Abstract

We have studied the effect of various agents on the decreases in striatal levels of dopamine (DA) and its metabolites which were observed 14 days after an intracerebroventricular (i.c.v.) administration of 50 μg 6-hydroxydopamine (6-OHDA) to mice. A pretreatment of mice with either a tyrosine hydroxylase inhibitor (α-methyl-p-tyrosine), a D₂ receptor agonist (bromocriptine) or antagonist (haloperidol), or a vesicular uptake inhibitor (tetrabenazine) did not modify the 6-OHDA-induced decreases in DA and metabolites, indicating that DA synthesis, vesicular storage and neuronal firing rates are not mainly involved in the 6-OHDA-induced toxicity on the DA neurons. Conversely, a pretreatment with L-DOPA + benserazide potentiated the 6-OHDA-induced decreases in striatal levels of DA, homovanillic acid and 3-methoxy-tyramine. This effect was not due to an increased 6-OHDA uptake via the neuronal carrier since a pretreatment with L-DOPA + benserazide, performed 1-1.5 h before sacrifice, decreased the apparent affinity of the uptake, an effect which disappeared when considering the total DA concentration present in incubation medium ([³H]DA and cold released DA). In conclusion, potentiation of the 6-OHDA neurotoxicity by L-DOPA rises again the important problem of the safety of the latter drug in therapeutics.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001841
to stream PascalFrancis, to step Curation: 001805

Links to Exploration step

Pascal:96-0044785

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice</title>
<author><name sortKey="Naudin, B" sort="Naudin, B" uniqKey="Naudin B" first="B." last="Naudin">B. Naudin</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS Fac. médecine pharmacie, URA 1969 lab. neuropsychopharmacologie exp.</s1>
<s2>76803 Saint Etienne du Rouvray</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, J J" sort="Bonnet, J J" uniqKey="Bonnet J" first="J.-J." last="Bonnet">J.-J. Bonnet</name>
</author>
<author><name sortKey="Costentin, J" sort="Costentin, J" uniqKey="Costentin J" first="J." last="Costentin">J. Costentin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0044785</idno>
<date when="1995">1995</date>
<idno type="stanalyst">PASCAL 96-0044785 INIST</idno>
<idno type="RBID">Pascal:96-0044785</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001841</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001805</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001742</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001742</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice</title>
<author><name sortKey="Naudin, B" sort="Naudin, B" uniqKey="Naudin B" first="B." last="Naudin">B. Naudin</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS Fac. médecine pharmacie, URA 1969 lab. neuropsychopharmacologie exp.</s1>
<s2>76803 Saint Etienne du Rouvray</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Normandie</region>
<region type="old region" nuts="2">Haute-Normandie</region>
<settlement type="city">Saint Etienne du Rouvray</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bonnet, J J" sort="Bonnet, J J" uniqKey="Bonnet J" first="J.-J." last="Bonnet">J.-J. Bonnet</name>
</author>
<author><name sortKey="Costentin, J" sort="Costentin, J" uniqKey="Costentin J" first="J." last="Costentin">J. Costentin</name>
</author>
</analytic>
<series><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="1995">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain research</title>
<title level="j" type="abbreviated">Brain res.</title>
<idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Dopaminergic neuron</term>
<term>Mouse</term>
<term>Nigrostriatal pathway</term>
<term>Oxidopamine</term>
<term>Parkinson disease</term>
<term>Potentiation</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Neurone dopaminergique</term>
<term>Voie nigrostriatale</term>
<term>Dopa</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Dopamine</term>
<term>Antiparkinsonien</term>
<term>Potentialisation</term>
<term>Parkinson maladie</term>
<term>Oxidopamine</term>
<term>Toxicité</term>
<term>Animal</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have studied the effect of various agents on the decreases in striatal levels of dopamine (DA) and its metabolites which were observed 14 days after an intracerebroventricular (i.c.v.) administration of 50 μg 6-hydroxydopamine (6-OHDA) to mice. A pretreatment of mice with either a tyrosine hydroxylase inhibitor (α-methyl-p-tyrosine), a D<sub>2</sub>
 receptor agonist (bromocriptine) or antagonist (haloperidol), or a vesicular uptake inhibitor (tetrabenazine) did not modify the 6-OHDA-induced decreases in DA and metabolites, indicating that DA synthesis, vesicular storage and neuronal firing rates are not mainly involved in the 6-OHDA-induced toxicity on the DA neurons. Conversely, a pretreatment with L-DOPA + benserazide potentiated the 6-OHDA-induced decreases in striatal levels of DA, homovanillic acid and 3-methoxy-tyramine. This effect was not due to an increased 6-OHDA uptake via the neuronal carrier since a pretreatment with L-DOPA + benserazide, performed 1-1.5 h before sacrifice, decreased the apparent affinity of the uptake, an effect which disappeared when considering the total DA concentration present in incubation medium ([<sup>3</sup>
H]DA and cold released DA). In conclusion, potentiation of the 6-OHDA neurotoxicity by L-DOPA rises again the important problem of the safety of the latter drug in therapeutics.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8993</s0>
</fA01>
<fA02 i1="01"><s0>BRREAP</s0>
</fA02>
<fA03 i2="1"><s0>Brain res.</s0>
</fA03>
<fA05><s2>701</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NAUDIN (B.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BONNET (J.-J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>COSTENTIN (J.)</s1>
</fA11>
<fA14 i1="01"><s1>CNRS Fac. médecine pharmacie, URA 1969 lab. neuropsychopharmacologie exp.</s1>
<s2>76803 Saint Etienne du Rouvray</s2>
<s3>FRA</s3>
</fA14>
<fA20><s1>151-157</s1>
</fA20>
<fA21><s1>1995</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>12895</s2>
<s5>354000059980500180</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>96-0044785</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain research</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We have studied the effect of various agents on the decreases in striatal levels of dopamine (DA) and its metabolites which were observed 14 days after an intracerebroventricular (i.c.v.) administration of 50 μg 6-hydroxydopamine (6-OHDA) to mice. A pretreatment of mice with either a tyrosine hydroxylase inhibitor (α-methyl-p-tyrosine), a D<sub>2</sub>
 receptor agonist (bromocriptine) or antagonist (haloperidol), or a vesicular uptake inhibitor (tetrabenazine) did not modify the 6-OHDA-induced decreases in DA and metabolites, indicating that DA synthesis, vesicular storage and neuronal firing rates are not mainly involved in the 6-OHDA-induced toxicity on the DA neurons. Conversely, a pretreatment with L-DOPA + benserazide potentiated the 6-OHDA-induced decreases in striatal levels of DA, homovanillic acid and 3-methoxy-tyramine. This effect was not due to an increased 6-OHDA uptake via the neuronal carrier since a pretreatment with L-DOPA + benserazide, performed 1-1.5 h before sacrifice, decreased the apparent affinity of the uptake, an effect which disappeared when considering the total DA concentration present in incubation medium ([<sup>3</sup>
H]DA and cold released DA). In conclusion, potentiation of the 6-OHDA neurotoxicity by L-DOPA rises again the important problem of the safety of the latter drug in therapeutics.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie nigrostriatale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nigrostriatal pathway</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía nigroestriatal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Potentialisation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Potentiation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Potencialización</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="GER"><s0>Giftigkeit</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Animal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Animal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Animal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Souris</s0>
<s5>54</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Mouse</s0>
<s5>54</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Ratón</s0>
<s5>54</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>35</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>35</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>35</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>36</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>36</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>36</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>022</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>France</li>
</country>
<region><li>Haute-Normandie</li>
<li>Région Normandie</li>
</region>
<settlement><li>Saint Etienne du Rouvray</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bonnet, J J" sort="Bonnet, J J" uniqKey="Bonnet J" first="J.-J." last="Bonnet">J.-J. Bonnet</name>
<name sortKey="Costentin, J" sort="Costentin, J" uniqKey="Costentin J" first="J." last="Costentin">J. Costentin</name>
</noCountry>
<country name="France"><region name="Région Normandie"><name sortKey="Naudin, B" sort="Naudin, B" uniqKey="Naudin B" first="B." last="Naudin">B. Naudin</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001742 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001742 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:96-0044785
   |texte=   Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice

Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri